other material
confidence high
sentiment positive
materiality 0.60
Elite Pharmaceuticals reports positive bioequivalence for undisclosed anticonvulsant generic drug
ELITE PHARMACEUTICALS INC /NV/
- Pivotal BE study successful; generic product bioequivalent to branded anticonvulsant under fasting conditions.
- IQVIA reports $840M combined branded and generic sales for the 12 months ending April 2026.
- Elite to compile data and file ANDA with FDA; no specific timeline provided.
- Study was open-label, randomized, single-dose crossover in healthy adult subjects.